Cambridge, UK; 17 December 2019. Atlantic Healthcare plc (“Atlantic Healthcare” or “Company”), a specialist pharmaceutical company focused on acquiring, developing and commercialising therapeutics that address unmet patient needs and rare diseases, today announces it will present at the Biotech Showcase conference, held in San Francisco from January 13-15, 2020.

Atlantic Healthcare owns exclusive worldwide rights to a blended pipeline targeting multiple gastrointestinal (GI) diseases and patient groups, comprising Phase 2 and Phase 3 ready programmes, with a potential to establish new classes of treatments. These include alicaforsen, a validated anti-inflammatory approach via down regulation of cell trafficking, and renzapride: a validated approach for treating GI motility disorders.

The Biotech Showcase is an investor and networking conference, providing private, small- and mid-cap biotech companies an opportunity to present and meet with investors and biopharmaceutical executives.

It is being held January 13-15, alongside the J.P. Morgan Healthcare Conference and Atlantic Healthcare’s presentation of the company and its investor highlights will take place at 4.45pm on Tuesday January 14 at the Hilton San Francisco, Union Square.

If you would like to meet with the Atlantic team please send an email to investors@atlantichc.com.

About Atlantic Healthcare

Atlantic Healthcare plc is focused on acquiring, developing and commercialising therapeutics that can address unmet needs of patients who are managed by healthcare professionals in hospital and specialist care environments. The Company owns the exclusive worldwide rights to alicaforsen, a novel antisense drug. Recently, it also acquired the global rights to renzapride, which has the potential to address the unmet needs of multiple patient groups with gastrointestinal motility disorders.

Atlantic Healthcare intends to commercialise its products in Europe and the U.S. using a specialist sales team targeting healthcare professionals based in hospitals and specialist care centres. The Company plans to partner with established pharmaceutical companies to commercialise its products in the rest of the world.

The Company is led by an experienced international Board and Leadership Team, with deep roots and a proven track record in the pharmaceutical industry.

Forward Looking Statements

While Atlantic Healthcare believes any forward-looking statements in this press release are accurate, the statements represent Atlantic Healthcare’s beliefs only as of the date of this press release. A number of factors could cause actual events or results to differ materially from those indicated by such statements. These forward-looking statements involve risks and uncertainties. In addition, risks and results in clinical trials may not be indicative of risks or results from later stage or larger scale trials, and there is no assurance of regulatory approval. Existing and prospective investors should not place undue reliance on the forward-looking statements contained in a press release and instead should make their own determinations as to the reliability of such statements. Atlantic Healthcare undertakes no intent or obligation to update the information contained in this press release as new information becomes available.

For more information please contact:
Atlantic Healthcare
James Hansord
+44 1799 619 414
james.hansord@atlantichc.com

Investor Relations and Media
LifeSci Advisors
Chris Maggos
+41 79 367 62 54
chris@lifesciadvisors.com

European Investor Relations and Media
Consilium Strategic Communications
Melissa Gardiner / Matthew Neal
+44 20 3709 5700
atlantichealthcare@consilium-comms.com